这部分患者的HER2水平介于HER2阴性和HER2过表达之间,他们的治疗和预后一直不明确。2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 low status in early-stage invasive lobular carcinoma of the breast: associate...
Provides an international platform for the discussion and resolution of ongoing controversies in breast cancer treatment. For over 35 years, it has served as a reliable resource for a wide audience of researchers and professionals. With 800K+ article downloads each year, it offers a high visibilit...
Early breast cancer Adjuvant therapy Immunotherapy Radiation therapy Survivorship 1. Introduction 2023 was marked by long-awaited research results that directly influence early breast cancer management. Several studies shared a common objective of tailoring treatment intensity according to individual risk. In...
William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing unmet needs at ASCO 2024. This is a modal window. The Playback API request failed for an ...
It is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation, the FDA said on Friday. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test. ...
《乳腺癌研究和治疗》(Breast Cancer Research And Treatment)是一本以医学-肿瘤学综合研究为特色的国际期刊。该刊由Springer US出版商创刊于1981年,刊期Semimonthly。该刊已被国际重要权威数据库SCIE收录。期刊聚焦医学-肿瘤学领域的重点研究和前沿进展,及时刊载和报道该领域的研究成果,致力于成为该领域同行进行快速学术...
Track 9: Breast Cancer Management Breast cancer management typically includes a combination of surgery, chemotherapy, radiotherapy, and targeted therapies. Treatment plans are tailored to the patient's specific cancer type and characteristics. New treatments, like cryoablation, offer alternatives for smaller...
Breast cancerHypofractionated radiation therapyNeoadjuvant chemotherapySurgical de-escalationTumor bed boost? 2023 Soci茅t茅 fran?aise de radioth茅rapie oncologique (SFRO)Radiation therapy is a corner stone of breast cancer treatment as it has been shown postoperatively that it improves local control ...
At ASCO 2024, Avan J. Armaghani, MD, highlights two key presentations. First, a retrospective study on adjuvant endocrine therapy in ER-low breast cancer (1%-10% ER-positivity) demonstrated that patients who skipped this therapy had significantly worse overall survival, especially those who receiv...
Find the latest Breast Cancer news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.